Bibliography
- AMERICAN CANCER SOCIETY: Breast Cancer Facts and Figures 2005-2006. (2005):1-32.
- FISHER B, COSTANTINO JP, WICKERHAM DL et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. (1998) 90(18):1371-1388.
- DELMAS PD, BJARNASON NH, MITLAK BH et al.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New Eng. J. Med. (1997) 337:1641-1647.
- CLEMENS J, BENNETT DR, BLACK LJ, JONES C: Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sciences (1983) 32:2869-2875.
- BUZDAR AU, MARCUS C, HOLMES F, HUG V, HORTOBAGYI G: Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology (1988) 45:344-345.
- ETTINGER B, BLACK DM, MITLAK BH, KNICKEBOCKER RK, NICKELSEN T, GENANT HK: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA (1999) 282(7):637-645
- CUMMINGS SE, ECKERT S, KRUEGER KA et al: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE trial. JAMA (1999) 281:2189-2197.
- CAULEY JA, NORTON L, LIPPMAN ME et al: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res. Treat. (2001) 65:125-134.
- MARTINO S, CAULEY JA, BARRETT-CONNOR E et al: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl. Cancer Inst. (2004) 96(23):1751-1761.
- WALSH B, KULLER L, WILD R et al.: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA (1998) 279:1445-1451.
- WALSH B, PAUL S, WILD R et al.: The effects of hormone replacement therapy and raloxifene on c-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. (2000) 85:214-218.
- MOSCA L, BARRETT-CONNOR E, WENGER NK et al.: Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am. J. Cardiol. (2001) 88:392-395.
- BARRETT-CONNER E, MOSCA L, COLLINS P et al.: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. New Engl. J. Med. (2006) 355:125-137.
- GAIL MH, BRINTON LA, BYAR DP et al.: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst. (1989) 81:1879-1886.
- VOGEL VG, COSTANTINO JP, WICKERHAM DL et al.: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA (2006) 295:2727-2741.
- WICKERHAM DL, COSTANTINO JP, VOGEL V et al.: The Study of Tamoxifen and Raloxifene (STAR): initial findings from the NSABP P-2 breast cancer prevention study. J. Clin. Oncol. (2006) 24(18S):LBA5.
- LAND SR, WICKERHAM DL, COSTANTINO JP et al.: Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA (2006) 295:2742-2751.